99732 - Optimising statin therapy - National Case Study
- : Online
This interactive online case study is designed to assist GPs to update their knowledge and support best practice in relation to assessing absolute cardiovascular risk before considering lipid-modifying medicines, adequately trialling statin therapy before considering another agent, and assessing and managing statin-associated muscle symptoms (SAMS) appropriately.
The 1-hour module incorporates questions relating to a clinical scenario, with immediate feedback reflecting best practice, expert commentaries and assessment questions.
We have come a long way with lipid management in Australian general practice. This interactive case study will explore the latest news and evidence that can further enhance and reinforce patient care including:
• Who should be on lipid-modifying medicines - guidelines continue to reinforce a cardiovascular risk approach to prescribing lipid-modifying medicines. However, there is evidence that decisions to start therapy are being based on individual risk factors, or inaccurate risk estimates – leading to under or over prescribing of statin therapy.
• How to optimise statin therapy – an adequate trial includes titrating to maximal tolerated dose and checking for adherence to medicines and lifestyle changes is recommended to optimise LDL-C lowering.
• What is true statin intolerance, particularly statin-associated muscle symptoms (SAMS), and how it can be assessed and managed.